Exelixis & Ryvu Partner to Push Dapolsertib Forward in Aggressive B‑Cell Lymphoma
Exelixis partners with Ryvu Therapeutics to advance dapolsertib in Phase‑II trials for aggressive, relapsed B‑cell non‑Hodgkin lymphoma—promising early safety and activity data.
2 minutes to read
